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Abstract We have shown previously that the cannabinoid
receptor agonist CP55940 microinjected into the
paraventricular nucleus of the hypothalamus (PVN) of
urethane-anaesthetized rats induces depressor and pressor car-
diovascular effects in the absence and presence of the CB1
antagonist AM251, respectively. The aim of our study was
to examine whether the hypotension and/or hypertension in-
duced by CP55940 given into the PVN results from its influ-
ence on glutamatergic and GABAergic neurotransmission.
CP55940 was microinjected into the PVN of urethane-
anaesthetized rats twice (S1 and S2, 20 min apart).
Antagonists of the following receptors, NMDA (MK801),
β2-adrenergic (ICI118551), thromboxane A2–TP
(SQ29548), angiotensin II–AT1 (losartan) or GABAA
(bicuculline), or the NO synthase inhibitor L-NAME were
administered intravenously 5 min before S2 alone or together
with AM251. The CP55940-induced hypotension was re-
versed into a pressor response by AM251, bicuculline and
L-NAME, but not by the other antagonists. The CP55940-
induced pressor effect examined in the presence of AM251
was completely reversed by losartan, reduced by about 50–
60 % by MK801, ICI118551 and SQ29548, prevented by
bilateral adrenalectomy but not modified by bicuculline and
L-NAME. Parallel, but smaller, changes in heart rate accom-
panied the changes in blood pressure. The bi-directional CB1
receptor-mediated cardiovascular effects of cannabinoids
microinjected into the PVN of anaesthetized rats depend on
stimulatory glutamatergic and inhibitory GABAergic inputs to
the sympathetic tone; the glutamatergic input is related to AT1,
TP and β2-adrenergic receptors and catecholamine release
from the adrenal medulla whereas the GABAergic input is
reinforced by NO.
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Introduction
Cannabinoids act mainly via CB1 and CB2 receptors and in-
fluence multiple functions of the organism (for review, see
Pertwee et al. 2010). Their complex cardiovascular effects
are related to various peripheral and central mechanisms (for
review, see Malinowska et al. 2012; Ibrahim and Abdel-
Rahman 2014). Their most pronounced cardiovascular effect
in anaesthetized rodents is a prolonged hypotension accom-
panied by a decrease in heart rate (HR) mediated mainly by
peripheral presynaptic CB1 receptors on sympathetic nerve
endings innervating resistance vessels and heart
(Malinowska et al. 2010, 2012; Kwolek et al. 2005;
Niederhoffer et al. 2003). The peripherally restricted CB1 an-
tagonist AM6545 reversed the decreases in blood pressure
(BP) and HR elicited by the intravenous injection (i.v.) of
the cannabinoid agonist CP55940 into increases (Grzęda
et al. 2015). Central CB1 receptors are also involved in the
cannabinoid-induced decrease in BP in spontaneously hyper-
tensive rats (SHR). Thus, the effect of AM3506 (which in-
hibits fatty acid amide hydrolase (FAAH), the main hydrolytic
enzyme for the endocannabinoid anandamide (AEA)) was
reduced by the brain-penetrant CB1 receptor antagonists
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rimonabant or AM251, but not by AM6545 i.v. (Godlewski
et al. 2010).
The most distinct cardiovascular response to cannabinoids
in conscious rodents is the pressor response (Gardiner et al.
2009), which can also be detected in anaesthetized rodents as
the rapid phase that precedes the prolonged hypotension (e.g.
Kwolek et al. 2005; Malinowska et al. 2010, 2012). This stim-
ulatory effect, which has not been fully disclosed so far, is
related to a central site of action. Thus, CB1 receptor-
dependent increases in BP, plasma noradrenaline levels and/
or renal sympathetic nerve activity were observed after
intracisternal injection of WIN55212-2 and CP55940 to con-
scious rabbits (Niederhoffer and Szabo, 2000) and rats
(Ibrahim and Abdel-Rahman 2011) and after injection of
AEA, WIN55212-2 or HU-210 into the cisternal system
(Pfitzer et al. 2004), the rostral ventrolateral medulla
(RVLM) (Padley et al. 2003) or the dorsal periaqueductal gray
(dPAG) (Dean 2011) of anaesthetized rats.
The paraventricular nucleus of the hypothalamus (PVN)
represents one of the major integrative sites involved in the
control of autonomic cardiovascular responses in the brain
(Pyner 2009; Ferguson et al. 2008; Kc and Dick 2010). We
found that AEA, its stable analogue methanandamide
(MethAEA) or CP55940 injected intracerebroventricularly
(i.c.v.) (Malinowska et al. 2010) or into the PVN (Grzęda
et al. 2015) decreased BP and/or HR in urethane-
anaesthetized rats. However, in the presence of the CB1 recep-
tor antagonist AM251 i.v., the cardiodepressor effects of can-
nabinoids (given i.c.v. or into the PVN) were reversed into
pure pressor and tachycardic responses, which were inhibited
by the local microinjection of AM251. The CB2 receptor an-
tagonist SR144528 i.v. did not modify the cardiovascular ef-
fects of CP55940 given into the PVN. Bilateral PVN lesion
with kainic acid abolished pressor and depressor responses to
CP55940 (Grzęda et al. 2015).
Cannabinoid CB1 receptors are located mainly presynapti-
cally inhibiting the release of various neurotransmitters in-
cluding glutamate and GABA (Schlicker and Kathmann
2001). Regulation of food intake and energy homeostasis
(Busquets-Garcia et al. 2015) and stress response (Senst and
Bains 2014) are influenced in opposite direction by CB1 re-
ceptors in the PVN according to their localization on different
types of neurons (e.g. glutamatergic and GABAergic).
Similarly, the sympathetic tone controlling the cardiovascular
system results from the direct balance between stimulatory
and inhibitory inputs, depending on glutamatergic and
GABAergic neurotransmission in the PVN (Fig. 5), respec-
tively. Thus, it is possible that the bi-directional CB1 receptor-
mediated cardiovascular effects of CP55940 given into the
PVN (Grzęda et al. 2015) result from the CB1 receptor-
dependent modification of glutamatergic and GABAergic
neurotransmission in the PVN. We have previously shown
that the increase in BP induced by AEA (i.c.v.) was mediated
by central β2-adrenergic, N-methyl-D-aspartate (NMDA) and
thromboxane A2 (TXA2) TP receptors (Malinowska et al.
2010). The two main neurotransmission systems in the PVN
are indirectly modified e.g. by β2, TP and angiotensin II (Ang
II) AT1 receptors and by nitric oxide (NO) (Pyner 2009;
Ferguson et al. 2008; Kc and Dick 2010). Thus, the aim of
our study performed on urethane-anaesthetized rats was to
examine whether the depressor and/or pressor cardiovascular
effects induced by CB1 receptor activation by CP55940 in the
PVN results from its influence on glutamatergic and
GABAergic neurotransmission and/or additional factors (β2,
TP and AT1 receptors as well as NO) indirectly modifying the
latter two systems.
Materials and methods
Male normotensive Wistar rats (weighing 280–350 g) with
free access to food pellets and water were used. All surgical
procedures and experimental protocols were in accordance
with European and Polish legislation and were approved by
the local Animal Ethics Committee in Białystok (Poland).
Placement of a cannula for drug administration
into the PVN
Rats were anaesthetized intraperitoneally (i.p.) with pentobar-
bitone sodium (300 μmol/kg) and placed in a stereotaxic in-
strument (Stoelting WPI, Wood Dale, IL, USA). Stainless
cannulae (outer and inner diameter of 0.5 and 0.3 mm, respec-
tively) were stereotaxically implanted on the right side. The
coordinates for the PVN were 1.5 mm caudal to the bregma,
0.5 mm lateral to the midline and 8 mm below the skull sur-
face. Cannulae were fastened to the skull with acrylic cement.
Rats were protected against infections by topical administra-
tion of the antibiotic doxycycline. The rats were then returned
to their individual cages and allowed to recover.
Anaesthetized rats
At least 7 days later, rats were anaesthetized i.p. with urethane
(14 mmol/kg). The trachea was cannulated. Systolic BP
(SBP), mean BP (MBP) and diastolic BP (DBP) were mea-
sured from the right carotid artery via a transducer (ISOTEC;
Hugo Sachs Elektronik–Harvard Apparatus GmbH, March,
Germany). HR was recorded from the ECG by means of sub-
cutaneous electrodes. Body temperature was maintained con-
stant at approximately 37 °C using a heating pad (Bio-Sys-
Tech, Białystok, Poland) and monitored by a rectal probe
transducer (Physitemp BAT10; Physitemp Instruments, Inc.,
Clifton, NJ, USA). The left femoral vein was cannulated for
i.v. injection of drugs administered in a volume of 0.5 mL/kg.
The right femoral vein was prepared for infusion of
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prostaglandin F2α (PGF2α) by means of a Graseby 3100 sy-
ringe pump (Graseby Medical, Watford, Herts, UK). After
surgical procedures, animals were gently placed on their ab-
domen and cardiovascular parameters were allowed to stabi-
lize. Twenty minutes later, experiments were performed.
Experimental protocol
Agonists of NMDA receptors (NMDA; 1 mmol/rat,
Kawabe et al. 2008) or cannabinoid receptors (CP55940;
0.1 nmol/rat, Grzęda et al. 2015) were administered into
the PVN twice (S1 and S2, 20 min apart). PVN microin-
jections were administered slowly in a volume of 100 nL
per rat and were completed within 1 min. We recorded
agonist-induced maximal decreases or increases in the
particular cardiovascular parameters that persisted for at
least 5 s. Moreover, the non-selective nitric oxide syn-
thase inhibitor L-NAME 37 μmol/kg (Gordish and
Beierwaltes 2014) and the following antagonists were
used: MK801 1 μmol/kg (NMDA receptor; Malinowska
et al. 2010), ICI118551 1 μmol/kg (β2-adrenoceptor;
Malinowska et al. 2010), SQ29548 1 μmol/kg (thrombox-
ane A2 receptor (TP); Malinowska et al. 2010), losartan
10 μmol/kg (angiotensin II receptor (AT1); Kwolek et al.
2005) and bicuculline 5 μmol/kg (GABAA receptor;
Elsersy et al. 2006). The latter antagonists/blockers or
their solvents were administered i.v. alone or together
with the CB1 receptor antagonist AM251 3 μmol/kg
(Grzęda et al. 2015) 5 min before S2. In some experi-
ments, bilateral acute adrenalectomy or a sham operation
was performed 10 min before the second CP55940 admin-
istration. Adrenalectomy was done through two dorsolat-
eral skin and muscular incisions. The adrenal glands were
pulled out by holding the periadrenal fat and then excised.
Sham operated animals were handled in the same way
except that the adrenals were not removed. L-NAME in-
creased DBP to about 80–90 mmHg. Since this effect did
not recover during S2 and since the amplitude of
vasopressor/vasodepressor effects is dependent on the
basal BP (e.g. Kwolek et al. 2005), PGF2α (0.17–
1.47 μmol/kg/h) was infused to control animals to ensure
a basal DBP comparable to that of L-NAME-treated rats.
At the end of the experiments, correct cannula placement
was confirmed histologically and analysed by light mi-
croscopy. Only animals for which the correct placement
of the guide cannula to the PVN was confirmed were
included in this study.
Data analysis
Results are given as means ± SEM; n refers to the number of
rats. In order to quantify the effects of antagonists on the
cardiovascular effects of NMDA or CP55940, the agonist-
induced maximal decreases or increases in BP and HR during
S1 and S2 were calculated as percentage of the respective basal
SBP, DBP, MBP and HR immediately before injection of the
particular agonist. This procedure was chosen to minimize the
influence of natural inter-subject variability on final data. For
comparison of the mean values, the t test for paired and un-
paired data was used, as appropriate. When two or more
groups were compared with the same control, one-way anal-
ysis of variance (ANOVA) followed by Dunnett test was used.








(Tocris Cookson, Bristol, UK); L-NAME (Nω-nitro-L-argi-
nine-methyl ester); losartan monopotassium salt (Cayman
Chemicals, Ann Arbor, MI, USA); MK801 [((5R,10S)-(+)-5-
methyl-10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5,10-im-
ine hydrogen maleate], NMDA (N-methyl-D-aspartic acid)
(Sigma-Aldrich); SQ29548 [([1S-[1α, 2α(Z), 3α, 4α]]-
7-[3-[[2-[(phenylamino)carbonyl]hydrazino]methyl]-7-
oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid] (Cayman
Chemicals); pentobarbitone sodium (Biowet, Puławy,
Poland); PGF2α; urethane (Sigma-Aldrich).
Drugs were dissolved in saline with the following excep-
tions: AM251 in a mixture of ethanol, Cremophor El, DMSO
and saline (1:1:1:9.5); SQ29548 in a mixture of saline and
DMSO (20:1); CP55940 was dissolved in 19 % solution of
cyclodextrin. Solvents for agonists microinjected into the
PVN or for particular antagonists/blockers given i.v. did not
modify basal BP and HR.
Results
General
Basal SBP, DBP, MBP and HR measured immediately before
the first (S1) and the second (S2) microinjection of NMDA or
CP55940 into the PVN are given in Table 1. In animals not
treated with any receptor antagonists, values of basal cardio-
vascular parameters were comparable before S1 and S2,
confirming that the cardiovascular effects induced by agonists
during S1 ceased before S2. Basal BP and HRwere not altered
by i.v. administration of the following antagonists: AM251
(CB1 receptors), MK801 (NMDA receptors), losartan (AT1
receptors), SQ29548 (TP receptors), ICI118551 (β2-
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adrenoceptors), and bicuculline (GABAA receptors) and by
bilateral adrenalectomy. The NO synthesis inhibitor L-
NAME given i.v. alone or together with AM251 increased
SBP, DBP and MBP by about 20–30 mmHg but did not affect
basal HR. In the related control group, PGF2α was infused to
adjust basal BP values to those in rats treated with L-NAME
(Table 1).
Influence of the CB1 receptor antagonist AM251
on the cardiovascular effects of NMDA and CP55940
given into the PVN
As shown in Fig. 1, the first (S1) microinjection of
NMDA (1 mmol/rat) into the PVN increased SBP, DBP,
MBP and HR by about 34, 92, 54 and 39 % of basal
values (i.e. by 41 ± 6; 45 ± 5 and 41 ± 4 mmHg and
148 ± 10 beats/min; n = 4, respectively). The second
administration of the agonist (S2) into the PVN of the
same rat induced comparable increases in BP and HR.
The pressor response of NMDA lasted for 550 ± 87 s,
and the increase in HR for 724 ± 46 s (n = 4). The can-
nabinoid CB1 antagonist AM251 3 μmol/kg i.v. dimin-
ished the NMDA-induced increases in SBP, DBP, MBP
and HR by about 50–60 % (Fig. 1).
Similarly to our previous observations (Grzęda et al. 2015),
the microinjection of CP55940 (0.1 nmol/rat) into the PVN
decreased SBP, DBP,MBP and HR during S1 by about 15, 25,
20 and 5 % of basal values (i.e. by 16 ± 1; 13 ± 1 and
14 ± 1 mmHg and 17 ± 1 beats/min, respectively; n = 8;
Fig. 2a). The cardiovascular effects of CP55940 lasted for
about 2 min (for details, see Grzęda et al. 2015). Similar de-
creases in BP and HR were obtained during S1 in response to
microinjection of CP55940 into the PVN before administra-
tion of particular antagonists (see S1 in Figs. 2, 3, and 4).
However, in the presence of AM251 3 μmol/kg (independent
of two various solvents for particular antagonists) i.v.,
Table 1 Basal systolic, diastolic and mean blood pressure (SBP, DBP andMBP in mmHg) and heart rate (HR in beats/min) immediately before S1 or
S2 in urethane-anaesthetized rats
Agonist AM251 Antagonist (i.v.) Dosea Number Before S1 Before S2
SBP DBP MBP HR SBP DBP MBP HR
NMDA − − − 4 121 ± 8 49 ± 4 76 ± 9 376 ± 18 116 ± 14 48 ± 4 74 ± 8 380 ± 18
+ − − 4 118 ± 5 67 ± 7 79 ± 7 378 ± 14 126 ± 4 60 ± 9 80 ± 7 396 ± 18
CP55940 + Solventb − 8 87 ± 8 54 ± 4 66 ± 5 334 ± 8 91 ± 7 57 ± 3 65 ± 4 334 ± 7
− MK801 1 4 103 ± 5 45 ± 3 60 ± 1 349 ± 18 102 ± 7 47 ± 3 64 ± 3 348 ± 13
+ MK801 1 4 117 ± 7 66 ± 7 85 ± 6 352 ± 9 118 ± 5 66 ± 5 85 ± 3 345 ± 9
− ICI118551 1 4 96 ± 6 61 ± 8 75 ± 5 360 ± 6 96 ± 5 60 ± 6 76 ± 5 357 ± 3
+ ICI118551 1 5 87 ± 3 55 ± 2 66 ± 3 353 ± 6 86 ± 3 55 ± 2 66 ± 3 343 ± 9
− Losartan 10 4 104 ± 4 65 ± 6 73 ± 7 344 ± 6 101 ± 3 63 ± 5 73 ± 7 343 ± 5
+ Losartan 10 4 101 ± 5 57 ± 4 72 ± 4 329 ± 12 98 ± 5 57 ± 4 72 ± 4 327 ± 12
− Bicuculline 5 4 84 ± 2 54 ± 4 66 ± 3 354 ± 8 83 ± 4 52 ± 4 66 ± 3 357 ± 8
+ Bicuculline 5 4 73 ± 2 46 ± 1 59 ± 1 340 ± 26 77 ± 2 48 ± 1 62 ± 2 318 ± 16
+ Solventc − 4 89 ± 8 56 ± 6 70 ± 6 345 ± 16 93 ± 5 53 ± 4 67 ± 5 343 ± 13
− SQ29548 1 4 98 ± 7 57 ± 5 71 ± 5 365 ± 11 96 ± 6 58 ± 4 73 ± 6 367 ± 11
+ SQ29548 1 4 87 ± 6 60 ± 8 72 ± 8 348 ± 17 87 ± 5 60 ± 7 71 ± 7 336 ± 9
− L-NAMEd 27 4 108 ± 6 71 ± 6 90 ± 6 394 ± 25 127 ± 8+,* 94 ± 10+,* 109 ± 11+,* 398 ± 18
+ L-NAMEd 27 4 87 ± 3 53 ± 4 61 ± 1 334 ± 14 110 ± 6+ 79 ± 8+,* 97 ± 8+,* 332 ± 10
+ PGF2α
d − 4 90 ± 4 58 ± 8 64 ± 13 336 ± 11 115 ± 9+ 88 ± 9+,* 95 ± 7+,* 316 ± 4
+ Sham − 4 78 ± 4 52 ± 2 61 ± 3 335 ± 7 78 ± 3 54 ± 1 64 ± 3 332 ± 6
+ Adrenalectomy − 4 81 ± 3 45 ± 2 56 ± 3 317 ± 8 80 ± 7 45 ± 3 57 ± 4 324 ± 9
NMDA (1 mmol/rat) or CP55940 (0.1 nmol/rat) was injected into the paraventricular nucleus twice (S1-S2) 20 min apart. Antagonists or their solvents
(alone or in combination with AM251 3 μmol/kg) were given 5 min before S2. Data are given as the means ± SEM of n experiments
a Doses of antagonists/blockers are given in μmol/kg
b Solvents for MK801, ICI118551, losartan and bicuculline
c Solvent for SQ29548. PGF2α was infused at a dose of 0.17–1.47 μmol/kg/h
d Basal SBP, MBP and DBP values before S2 (i) are higher (
+P < at least 0.05) than the respective values before S1 and (ii) are higher (*P < at least 0.05)
or tend to be higher than the respective values before S2 in the presence of solvent
b (for the sake of simplicity, comparators are marked with italics in the
table)
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CP55940 increased SBP, DBP, MBP and HR by about 20, 25,
25 and 5 %, (i.e. by 18 ± 2; 14 ± 1 and 15 ± 1 mmHg and
16 ± 1 beats/min, respectively; n = 8) (Figs. 2a, 3a, and 4).
Influence of NMDA, angiotensin AT1, thromboxane TP
and β2-adrenoceptor antagonists on the cardiovascular
effects of CP55940
In contrast to AM251, the hypotension and the bradycardia
induced by microinjection of CP55940 (0.1 nmol/rat) into the
PVN (S1) were not modified (see S2) by the i.v. administration
of antagonists of AT1, NMDA, TP receptors and β2-
adrenoceptors, i.e., losartan (10 μmol/kg; Fig. 2b), MK801
(1 μmol/kg; Fig. 2c), SQ29584 (1 μmol/kg; Fig. 2d) and
ICI118551 (1 μmol/kg; Fig. 2e), respectively.
Next, we examined how the pressor and tachycardic
effects of CP55940 (0.1 nmol/rat) given into the PVN
obtained in the presence of AM251 are affected by the
four antagonists. Losartan completely reversed the
CP55940-stimulated increases in BP and HR to hypoten-
sive and bradycardic effects which were very similar to
the responses induced by CP55940 in the absence of
AM251 (Fig. 2b). MK801 (Fig. 2c), SQ29584 (Fig. 2d)
and ICI118551 (Fig. 2e) diminished the CP55940-induced
increases in SBP, DBP and MBP by about 60–70, 50–60
and 70–80 %, respectively but they did not affect the
CP55940-stimulated increases in HR.
Influence of a GABAA receptor antagonist and an NO
synthase inhibitor on the cardiovascular effects
of CP55940
The GABAA receptor antagonist bicuculline (5 μmol/kg, i.v.;
Fig. 3a) and the NO synthase inhibitor L-NAME (37μmol/kg,
i.v.; Fig. 3b) like AM251 reversed the depressant effects of
CP55940 (0.1 nmol/rat given into the PVN) on SBP, DBP,
MBP and HR into stimulatory ones. The CP55940-induced
increases in SBP, DBP and MBP and HR in the presence of
bicuculline were not affected when, in addition, AM251
(3μmol/kg) was given i.v. (Fig. 3a) and they were comparable
to those obtained in the presence of AM251 only.
By contrast, the CP55940-induced increases in DBP and
MBP (but not those in SBP and HR) obtained in the presence
of L-NAME were by about 45 and 65 % lower than those
determined in the presence of AM251 (compare Fig. 3a, b).
Moreover, the CB1 receptor antagonist enhanced the
CP55940-induced increases in DBP and MBP (but not those
in SBP and HR) obtained in the presence of L-NAME by
about 75 and 80 %, respectively (Fig. 3b). Since L-NAME
increased the level of the basal BP by about 20–30 mmHg
(Table 1), additional experiments were carried out in which
the baseline level of DBPwas increased to about 90mmHg by
i.v. infusion of PGF2α. Similar effects of AM251 on the
CP55940-induced increases in BP and HR occurred in the
absence (Fig. 3a) and presence of PGF2α (Fig. 3b). PGF2α
plus AM251 enhanced the CP55940-induced increases in
DBP and MBP (but not those in SBP and HR) obtained in
the presence of L-NAME by about 70 and 85 %, respectively
(Fig. 3b).
Influence of bilateral adrenalectomy
on the cardiovascular effects of CP55940
As shown in Fig. 4, bilateral adrenalectomy did not affect the
hypotensive and bradycardic responses to CP55940
(0.1 nmol/rat) given into the PVN but completely prevented
the pressor and tachycardic effects of CP55940 (given into the
PVN) observed after previous i.v. administration of AM251.
In sham operated animals, the CP55940-induced increases in
SBP, DBP and MBP and HR in the presence of AM251 were
similar to the changes observed under control conditions
(compare Figs. 4, 2a, and 3a).
Discussion
General
The present study was carried out to clarify whether the hy-
potension and/or hypertension induced by CP55940 given
into the PVN results from its influence on the two main
Fig. 1 Influence of AM251 on the increases in systolic, diastolic and
mean blood pressure (SBP, DBP, MBP) and heart rate (HR) induced by
NMDA microinjected into the paraventricular nucleus (PVN) in
urethane-anaesthetized rats. NMDA was administered twice (S1 and S2,
20 min apart). AM251 3 μmol/kg or its solvent was administered i.v.
5 min before S2. Results are calculated as percentage of basal values
determined immediately before S1 and S2 (see Table 1). Means ± SEM
of 4 rats. *P < 0.001 compared to the corresponding S1;
#P < 0.05;
###P < 0.001 compared to the corresponding S2 values without AM251
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neurotransmission systems (glutamatergic and GABAergic)
and/or is related to additional receptors and NO indirectly
modifying the two above systems. We performed experiments
on anaesthetized rats to continue our previous experiments
(Malinowska et al. 2010; Grzęda et al. 2015) and to reduce
stress since the activation of CB1 receptors inhibits the stress-
relevant neurons in the PVN (Crosby and Bains 2012). Like in
our previous studies, urethane was used as anaesthetic and
CP55940 served as cannabinoid receptor agonist.
Antagonists were administered i.v. since only a small
volume could be microinjected into the PVN and only
in this way, we were able to examine the CP55940-
induced decreases (S1) and increases (S2) in cardiovas-
cular parameters in one rat. On the other hand, this
route of administration does not allow us to exclude
that the effects of the antagonists may occur on central
sites apart from the PVN. The effectiveness of the an-
tagonists on centrally mediated effects after their i.v.
application was confirmed in our previous publications
(MK801, ICI118551 and SQ29548; Malinowska et al.
2010; Grzęda et al. 2015) or by other investigators (L-
NAME, bicuculline and losartan; Turnbull et al. 1998;
Elsersy et al. 2006; Busnardo et al. 2014). Moreover,
(1) we have shown previously that central but not pe-
ripheral NMDA, β2 and TP receptors are involved in
the pressor effect of cannabinoids since the effects of
AEA or MetAEA given i.v. were reduced by NMDA,
β2 and TP receptor antagonists in Bintact^ but not in
pithed rats (i.e. in a model in which the effects of drugs
involve peripheral sites only; Kwolek et al. 2005;
Malinowska et al. 2010). (2) The pressor responses to
AEA i.c.v. (obtained in the presence of a CB1 antago-
nist) were diminished by i.v. administration of NMDA,
β2 and TP antagonists (Malinowska et al. 2010). (3)
The AT1 receptor antagonist losartan i.v. did not modify
the cardiovascular effects of AEA i.v. (including its
pressor effect; Kwolek et al. 2005). Moreover, subcuta-
neous injection of losartan inhibits AT1 receptors (la-
belled by 125I-Ang II binding) in the rat PVN (Wang
et al. 2003). To the best of our knowledge, peripheral
GABAA receptors do not participate in the regulation of
the rat cardiovascular system.
Fig. 2 Influence of AM251 alone (a) and of AM251 plus losartan (b),
MK801 (c), SQ29548 (d) and ICI118551 (e) on the increases in systolic,
diastolic and mean blood pressure (SBP, DBP, MBP) and heart rate (HR)
induced by CP55940 microinjected into the paraventricular nucleus
(PVN) in urethane-anaesthetized rats. CP55940 was administered twice
(S1 and S2, 20 min apart). AM251 3 μmol/kg was administered i.v. 5 min
before S2 either together with saline (solvent for losartan, MK801 and
ICI118551) or the solvent for SQ29548 (a) or together with losartan
10 μmol/kg, MK801 1 μmol/kg, SQ29548 1 μmol/kg or ICI118551
1 μmol/kg (b–e). Results are calculated as percentage of basal values
determined immediately before S1 and S2 (see Table 1). Means ± SEM
of 4–8 rats. *P < 0.001 compared to the corresponding S1;
ΔP < 0.05;
ΔΔP < 0.01; ΔΔΔP < 0.001 compared to the S2 with AM251 and the
respective solvent
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Modification of the CP55940-induced hypotension
and bradycardia
Two main observations are in line with our working hypoth-
esis that the decrease in BP and HR in response to the micro-
injection of CP55940 into the PVN is related to the activation
of presynaptic inhibitory CB1 receptors on glutamatergic neu-
rons. Firstly, we confirmed that AM251 i.v. reversed the de-
pressant effects of CP55940 on BP and HR into stimulatory
ones (Grzęda et al. 2015). We cannot exclude the possibility
that the effect of AM251 i.v. is partially related to the inhibi-
tion of peripheral presynaptic inhibitory CB1 on sympathetic
nerve endings. However, the pressor effect of CP55940 given
into the PVN in the presence of AM251 i.v. was completely
reversed by AM251 microinjected into the PVN (Grzęda et al.
2015). The final integration of the sympathetic outflow by the
PVN results from the balance between stimulatory and inhib-
itory inputs depending on glutamate and GABA, respectively
(Fig. 5; Pyner 2009; Ferguson et al. 2008; Kc and Dick 2010).
In the PVN, presynaptic inhibitory CB1 receptors are localized
both on glutamatergic and GABAergic synapses (Senst and
Bains 2014); activation of CB1 receptors on GABAergic neu-
rons should result in hypertension. The question arises why in
our hands CP55940 primarily activates CB1 receptors on glu-
tamatergic neurons? Different feeding (Busquets-Garcia et al.
2015) or emotional states (Senst and Bains 2014) determine
the direction of final effects of endocannabinoids on CB1 re-
ceptors on glutamatergic and GABAergic transmission in the
PVN on food intake or stress. In our previous paper (Grzęda
et al. 2015), we suggested that the higher resting sympathetic
tone in urethane-anaesthetized rats (Carruba et al. 1987) may
lead to a stronger inhibitory effect of cannabinoids on gluta-
mate than on GABA release.
Secondly, similarly to AM251 (present paper and Grzęda
et al. 2015), blockade of GABAA receptors and NO synthesis,
i.e. of mechanisms that have an inhibitory influence on the
glutamatergic neurotransmission (Pyner 2009; Kc and Dick
2010), reversed the CP55940-induced hypotension and bra-
dycardia into pressor and tachycardic responses. As shown in
Fig. 5, GABA inhibits the stimulatory glutamatergic influence
via GABAA receptors (Li et al. 2006) and NO potentiates the
inhibitory effect of GABAergic transmission (Pyner 2009; Kc
and Dick 2010). Thus, the respective blockers bicuculline and
Fig. 3 Influence of AM251, bicuculline (a) and L-NAME (b) on the
increases in systolic, diastolic and mean blood pressure (SBP, DBP,
MBP) and heart rate (HR) induced by CP55940 microinjected into the
paraventricular nucleus (PVN) in urethane-anaesthetized rats. CP55940
was administered twice (S1 and S2, 20 min apart). AM251 3 μmol/kg
[given with saline (solvent for bicuculline, L-NAME and PGF2α)],
bicuculline 5 μmol/kg and/or L-NAME 37 μmol/kg were administered
i.v. 5 min before S2. In one series (b) with AM251 (but without L-
NAME), PGF2α 0.17–1.47 μmol/kg/h was infused to adjust basal
parameters before S2 to those in rats treated with L-NAME. Results are
calculated as percent of basal values determined immediately before S1
and S2 (see Table 1). Means ± SEM of 4–8 rats. *P < 0.001 compared to
the corresponding S1 values;
ΔP < 0.05 compared to S2 with L-NAME
only
Fig. 4 Influence of adrenalectomy on the increases in systolic, diastolic
and mean blood pressure (SBP, DBP, MBP) and heart rate (HR) induced
by CP55940 microinjected into the paraventricular nucleus (PVN) in
urethane-anaesthetized rats. Adrenalectomy or sham operation was
performed about 15 min before the second CP55940 microinjection.
AM251 3 μmol/kg was given i.v. 5 min before S2. Results are calculated
as percentage of basal values determined immediately before S1 and S2
(see Table 1). Means ± SEM of 4 rats. *P < 0.001 compared to the
corresponding S1;
ΔΔΔP < 0.001 compared to the S2 values in sham
operated rats
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L-NAME dis-inhibited the effects induced by GABA and NO
and reversed the depressor influence of CP55940 on cardio-
vascular parameters into a stimulatory one. The type of NO
synthase is unclear since L-NAME is a non-selective inhibitor
and both neuronal and endothelial NO synthase in the PVN
are involved in the modulation of the sympathetic tone (Lu
et al. 2015).
Bilateral adrenalectomy did not affect the CP55940-
induced hypotension and bradycardia. These results are in line
with our previous study and allow us to exclude the possibility
that catecholamines released from the adrenal medulla con-
tributed to the neurogenic cardiovascular responses
(Malinowska et al. 2001).
Modification of the CP55940-induced pressor
and tachycardic responses
The pressor responses to CP55940 given into the PVN were
routinely examined in the presence of AM251, which,
according to our hypothesis, primarily diminishes the inhibi-
tory effect of CB1 receptors on glutamatergic neurons. The
activation of presynaptic inhibitory CB1 receptors on
GABAergic neurons that tonically inhibit glutamatergic neu-
rotransmission should decrease the GABAergic inhibitory in-
put leading to increases in BP and HR. Indeed, AM251 did not
modify the CP55940-induced increase in BP obtained in the
presence of bicuculline and enhanced that determined in the
presence of L-NAME, suggesting that the CP55940 increased
BP acting predominantly at inhibitory presynaptic CB1 recep-
tors on GABAergic neurones or by increasing NO production.
Similarly, the microinjection of the CB1 receptor agonist
WIN55212-2 into the RVLM (Ibrahim and Abdel-Rahman
2011) or AEA into the dPAG (Dean 2011) increased BP via
inhibition of brainstem GABAergic transmission and by in-
creasing the NO level in the RVLM (Ibrahim and Abdel-
Rahman 2012). Colocalization of CB1 receptors and NO syn-
thase has been shown in the rat PVN (Zou et al. 2015). The
glutamate-based stimulatory output of the PVN is subject to a
tonic inhibition arising from GABA and NO (Pyner 2009; Kc
and Dick 2010). Both bicuculline (Li et al. 2006) and AM251
(Gyombolai et al. 2012) given into the PVN caused increases
in BP and/or HR, suggesting that the sympathetic tone is ton-
ically inhibited not only by the GABAergic but also by the
endocannabinergic system. The fact that the above antagonists
had no influence on basal cardiovascular parameters in our
study is probably related to the fact that they were adminis-
tered i.v. Since L-NAME increased BP by itself, we per-
formed additional experiments in which basal BP was in-
creased by PGF2α infusion to the level obtained after L-
NAME application. Our data show that compared to the L-
NAME group, AM251 further increased the CP55940-
induced effect on DBP and MBP regardless of whether the
basal BP was increased by L-NAME or PGF2α.
The AT1 antagonist losartan completely reversed the
CP55940-induced pressor and tachycardic effects into hypo-
tension and bradycardia. The NMDA, TP and β2 receptor
antagonists MK801, SQ29584, and ICI118551, respectively,
diminished the CP55940-induced pressor effects by about 50–
60 % without affecting the CP55940-stimulated increases in
HR. As shown in Fig. 5, AT1, TP and β2 receptors enhance
glutamatergic transmission, which is additionally increased by
the activation of NMDA receptors.
Our data suggest that AT1 receptors seem to play a major
role in the CP55940-induced stimulatory cardiovascular re-
sponses. The particularly strong effect of losartan might result
from the fact that Ang II in the PVN does not only increase the
glutamatergic tone (Pyner 2009; Kc and Dick 2010; Ferguson
et al. 2008; Nunn et al. 2011) but also inhibits the GABAergic
tone (via an inhibitory influence on NO or GABA; Chen and
Pan 2007; Nunn et al. 2011). Our results are in line with
findings by Gyombolai et al. (2012) who showed that CB1
receptors play a role in the hypertensive effects of angiotensin
Fig. 5 Possible mechanisms involved in the effect of the CB receptor
agonist CP55940 topically administered to the paraventricular nucleus
(PVN) on the sympathetic outflow and cardiovascular parameters.
Activation of presynaptic inhibitory CB1 receptors on glutamatergic
(Glu) neurones leads to a decrease in the sympathetic outflow (mainly
to resistance vessels and heart) and a fall in blood pressure. Activation of
presynaptic inhibitory CB1 receptors on GABAergic (γ-aminobutyric
acid) neurons leads to an increase in the sympathetic outflow (mainly of
the adrenal medulla) and in blood pressure. Activation of presynaptic
facilitatory (i) angiotensin II (Ang II) AT1, (ii) thromboxane A2 (TXA2)
TP and (iii) adrenaline (Adr) β2-adrenergic receptors increases whereas
activation of GABAA receptors decreases the release of glutamate. Nitric
oxide (NO) stimulates GABA release. For the sake of clarity, only
interactions examined in the present study have been shown in this
scheme. An inhibitory effect of Ang II and a facilitatory effect of
CP55940 on NO production although opposite in direction to the
effects usually obtained by AT1 and CB1 receptor activation,
respectively, are also indicated. stimulatory inputs;
inhibitory inputs. RVLM rostral ventrolateral medulla, IML
intermediolateral column
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II in the rat paraventricular nucleus since co-administration of
AM251 together with Ang II abolished the well-known pres-
sor effect of Ang II given into the PVN. Gyombolai et al.
(2012) suggested that the Ang II-induced hypertension is con-
nected with the activation of CB1 receptors, e.g. due to (1) the
heterodimerization of CB1 and AT1 receptors (Rozenfeld et al.
2011) or (2) Ang II–induced endocannabinoid release that
inhibits the GABAergic tone. In another study on the rat
PVN (Chen and Pan 2007), a direct inhibitory effect of Ang
II on GABAergic transmission, involving Gi/o proteins and
superoxide formation, has been suggested.
Electrical stimulation of the C1 area of the rostral ventro-
lateral medulla increased BP in rats in a manner sensitive to
intra-hypothalamic microinjection of the β2 antagonist
ICI118551 but not to the β1 antagonist atenolol (Ward-
Routledge et al. 1988). In addition, the PVN is richly inner-
vated by noradrenergic nerve terminals originating from the
brainstem, especially A1, A2 and A6 cell groups
(Cunningham and Sawchenko 1988). It contains more β2-
than β1-adrenoceptors (Rainbow et al. 1984). However, the
microinjection of the β2-adrenoceptor agonist fenoterol did
not modify BP and HR in anaesthetized rats, but authors have
used one dose of the agonist (5 nmol/rat) only (Tsushima et al.
1994). On the other hand, noradrenaline microinjected into the
PVN increased BP (Bachelard et al. 1992). Moreover,
ICI118551 but not atenolol diminished the pressor effect of
endothelin i.c.v., which may indirectly act via β2-
adrenoceptors (Ono and Kaneko 1995).
Bilateral adrenalectomy completely reversed the pressor
and tachycardic effects of CP55940 to hypotension and bra-
dycardia of a comparable magnitude as they were before
AM251 administration. Thus, we can conclude that the pres-
sor effect of CP55940 given into the PVN is completely relat-
ed to catecholamine release from the adrenal medulla but not
from sympathetic nerve endings. Similarly, microinjection of
a TXA2 mimetic into the PVN elevated plasma levels of
adrenaline but had little effect on plasma levels of noradrena-
line, suggesting that TP receptors are involved in the central
adrenomedullary outflow in rats (Murakami et al. 2002).
Perfusion of the PVN with NMDA increased, in a manner
sensitive to MK801, the local level of thromboxane B2 (the
inactive metabolite of TXA2), glutamate and GABA, the plas-
ma level of catecholamines (Okada et al. 2000; Kondo et al.
2015) and BP (Li and Pan 2007). We confirmed that microin-
jection of NMDA into the PVN increased BP and HR (e.g.
Kawabe et al. 2008) and showed for the first time that both
cardiovascular effects were diminished by AM251 given i.v.
We can exclude the possibility that AM251 inhibits presynap-
tic inhibitory CB1 receptors located mainly on peripheral sym-
pathetic nerve endings innervating resistance vessels and heart
(for review, see Malinowska et al. 2010) or on central gluta-
matergic neurons (for review, see Schlicker and Kathmann
2001) since in both cases an increase in BP would be
expected. The most plausible explanation of our data is that
AM251 inhibits presynaptic inhibitory CB1 receptors located
on central GABAergic neurons, thereby dis-inhibiting the
GABAergic tone and inhibiting the NMDA-induced stimula-
tory effects. The fact that AM251 increases basal BP in the
study by Gyombolai et al. (2012) but reduces the NMDA-
induced increase in BP in the present one might be related to
a normal and enhanced sympathetic tone, respectively
(discussed in Grzęda et al. 2015).
Conclusions
Stimulation of presynaptic inhibitory CB1 receptors on gluta-
matergic neurons in the PVN decreases BP and HR. Even if
due to the i.v. administration of the antagonists/blockers, other
locations cannot be excludedwith absolute certainty that our data
provide evidence that glutamatergic neurotransmission is proba-
bly increased by presynaptic facilitatory AT1, TP and β2-adren-
ergic heteroreceptors but inhibited by postsynaptic GABAA re-
ceptors (Fig. 5). On the other hand, stimulation of presynaptic
CB1 receptors onGABAergic neurones in the PVNmight inhibit
their inhibitory influence on glutamatergic neurotransmission,
thereby increasing the sympathetic tone and ultimately leading
to increases in BP andHR. The tone of the GABAergic neurones
might in turn be increased byNO. The final effect, i.e. depression
or stimulation of cardiovascular parameters, probably depends
on the level of the sympathetic tone. The increase and decrease in
BP (and HR) induced by the activation of CB1 receptors in the
PVN are dependent and independent of catecholamine release
from the adrenal medulla, respectively.
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